Li Lai: Plans to invest a total of 3 billion USD over the next ten years to fully expand supply chain capacity in China.

On March 11th, Lilly announced plans to invest $3 billion over the next ten years to expand its supply chain capacity in China, focusing on building a local production and supply system for oral solid formulations. The company will also focus on establishing production capabilities for the first orally administered small molecule GLP-1 receptor agonist, orforglipron.